Cell intrinsic Egr1 and Apc haploinsufficiency cooperate with Tp53 loss to induce AML
BM donor . | shRNA (%) . | T lymphoma or T-cell leukemia (%) . | Soft tissue sarcoma (%) . | AML (%) . |
---|---|---|---|---|
WT | Luc | 0/10 (0) | 0/10 (0) | 0/10 (0) |
Egr1+/− | Luc | 0/11 (0) | 1/11 (9) | 0/11 (0) |
Apcdel/+ | Luc | 0/11 (0) | 0/11 (0) | 0/11 (0) |
Egr1+/−, Apcdel/+ | Luc | 0/12 (0) | 0/12 (0) | 0/12 (0) |
WT | Tp53 | 0/10 (0) | 1/10 (10) | 0/10 (0) |
Egr1+/− | Tp53 | 2/10 (20) | 0/10 (0) | 0/10 (0) |
Apcdel/+ | Tp53 | 1/11 (9) | 0/11 (0) | 0/11 (0) |
Egr1+/−, Apcdel/+ | Tp53 | 1/12 (8) | 1/12 (8) | 2/12 (17)* |
BM donor . | shRNA (%) . | T lymphoma or T-cell leukemia (%) . | Soft tissue sarcoma (%) . | AML (%) . |
---|---|---|---|---|
WT | Luc | 0/10 (0) | 0/10 (0) | 0/10 (0) |
Egr1+/− | Luc | 0/11 (0) | 1/11 (9) | 0/11 (0) |
Apcdel/+ | Luc | 0/11 (0) | 0/11 (0) | 0/11 (0) |
Egr1+/−, Apcdel/+ | Luc | 0/12 (0) | 0/12 (0) | 0/12 (0) |
WT | Tp53 | 0/10 (0) | 1/10 (10) | 0/10 (0) |
Egr1+/− | Tp53 | 2/10 (20) | 0/10 (0) | 0/10 (0) |
Apcdel/+ | Tp53 | 1/11 (9) | 0/11 (0) | 0/11 (0) |
Egr1+/−, Apcdel/+ | Tp53 | 1/12 (8) | 1/12 (8) | 2/12 (17)* |
Mouse 1586 developed acute myelomonocytic leukemia; mouse 4524 developed CD19+ AML.